Paulo Alexandre Ribeiro Mora

Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

Richard T. Penson, Ricardo Villalobos-Valencia, David Cibula et al. · Journal of Clinical Oncology · 2019 · 26 citations

Medicine, Oncology, Pharmacology +14

Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?

Paulo Alexandre Ribeiro Mora, Sue Yazaki Sun, Luís Guillermo Coca Velarde et al. · Gynecologic Oncology · 2019 · 24 citations

Medicine, Obstetrics, Oncology +10

First-Line Paclitaxel and Carboplatin in Persistent/Recurrent or Advanced Cervical Cancer

Alvaro Ingles Garces, Paulo Alexandre Ribeiro Mora, Flávia Vieira Guerra Alves et al. · International Journal of Gynecological Cancer · 2013 · 22 citations

Medicine, Oncology, Pharmacology +13

Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend

Antônio Braga, Clymene de Souza Hartung Araújo, Paulo Alexandre Ribeiro Mora et al. · Gynecologic Oncology · 2020 · 12 citations

Medicine, Pharmacology, Pharmacotherapy +5